Preclinical Data of ANAVEX 1-41 and ANAVEX 2-73 Show Highly Potent Anti-Amnesic and Neuroprotective Activity Against Amyloid Beta (25-35) Peptide Toxicity in Alzheimer’s Disease (AD) Animal Models May 23, 2007
4-IBP, a sigma-1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vivo and sensitizes them in vitro to cytotoxic insults of proapoptotic and proautophagic drugs. May 11, 2007
Anavex Life Sciences Corp. Announces Research Agreement with University of Paris 5-Rene Descartes April 2, 2007
Anavex Life Sciences Corp. Announces its Preclinical Pipeline of Novel Oncology Therapies February 12, 2007
Anavex Life Sciences Corp. Appoints VP Business Development and VP Strategic Planning February 7, 2007
Anavex Life Sciences Corp. Outlines its Central Nervous System (CNS) Portfolio of Novel Therapeutics February 1, 2007
Anavex Life Sciences Corp. Acquires a Portfolio of Patents and Appoints Dr. Alexandre Vamvakides as CSO and Director January 31, 2007
Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl-channels. January 26, 2007
